{"entity":{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","aka":[],"tldr":"A phase 2 trial of eribulin and evexomostat in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer is a phase 2, randomised interventional study registered as NCT05570253 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 55 participants, started 2022-10-03 and due to reach its primary completion in 2027-10. Interventions recorded: Eribulin; SDX-7320; Placebo. Conditions listed: Breast Cancer; Metastatic Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining ≤10%; and HER2-negative defined as IHC 0 to 1+ at enrolling institution (note: if IHC is equivocal, non-amplified status by\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05570253","url":"https://clinicaltrials.gov/study/NCT05570253"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["eribulin","evexomostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05570253","phase":"2","setting":"\"A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast Cancer and Metabolic Dysfunction: The ARETHA Study","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05570253/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"},{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}